GlassScriptPhysician profile
Khan A Shabih
NPI 1285720524
$5,946.71
in general payments reported to CMS, 2019-2025
21 companies · $251 in 2025
The $251 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,075 · 2020: $871 · 2021: $1,103 · 2022: $1,137 · 2023: $1,303 · 2024: $206 · 2025: $251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,748 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,747.59 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,071.38 | 2019-2023 | Farxiga |
| Otsuka America Pharmaceutical, INC. | $979.70 | 2019-2025 | Jynarque |
| Amgen INC. | $885.83 | 2019-2023 | Tavneos |
| Vifor Pharma, INC. | $800.33 | 2019-2023 | Veltassa, Korsuva |
| Mallinckrodt Hospital Products INC. | $282.54 | 2020-2024 | Terlivaz, Acthar |
| Novo Nordisk INC | $273.94 | 2023-2025 | Ozempic |
| Novartis Pharmaceuticals Corporation | $229.37 | 2021-2025 | |
| Arbor Pharmaceuticals, INC. | $216.82 | 2019-2021 | |
| Glaxosmithkline, LLC. | $208.41 | 2021-2023 | Benlysta |
| Bayer Healthcare Pharmaceuticals INC. | $186.55 | 2022-2025 | |
| Aurinia Pharma U.S., INC. | $173.25 | 2021-2023 | Lupkynis |
| Horizon Therapeutics Plc | $162.55 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $97.17 | 2019-2025 | Ultomiris |
| Travere Therapeutics, INC. | $85.93 | 2022-2023 | |
| Opko Pharmaceuticals, LLC | $74.73 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nxstage Medical, INC. | $71.62 | 2019 | |
| Calliditas Therapeutics US INC. | $57.62 | 2022-2023 | Tarpeyo |
| Recordati_rare_diseases_inc. | $27.75 | 2021 | |
| Lilly USA, LLC | $23.32 | 2023 | Jardiance |
| Daiichi Sankyo INC. | $19.31 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.59 | 2023 | Jynarque |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khan Shabih listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.